Somatrogon

Somatrogon is a long-acting recombinant human growth hormone (rhGH) used in the treatment of growth hormone deficiency (GHD) in children and adults. It is designed to provide a more convenient dosing regimen compared to daily growth hormone injections.

Mechanism of Action

Somatrogon works by stimulating growth and cell reproduction in humans. It binds to the growth hormone receptor (GHR) on the surface of target cells, activating intracellular signaling pathways that promote growth and development. The long-acting nature of Somatrogon is achieved through the fusion of the growth hormone with a carrier protein, which extends its half-life in the bloodstream.

Indications

Somatrogon is primarily indicated for:

• Growth hormone deficiency in pediatric patients
• Growth hormone deficiency in adult patients

Administration

Somatrogon is administered via subcutaneous injection. The dosing frequency is typically once weekly, which is a significant improvement over the daily injections required for traditional growth hormone therapies.

Side Effects

Common side effects of Somatrogon include:

• Injection site reactions
• Headache
• Nausea
• Muscle pain

Serious side effects may include:

• Increased intracranial pressure
• Hyperglycemia
• Hypothyroidism

Pharmacokinetics

The pharmacokinetics of Somatrogon involve a prolonged half-life due to its molecular structure, allowing for sustained release and activity in the body. This results in stable growth hormone levels with less frequent dosing.

Related Pages

• Growth hormone
• Growth hormone receptor
• Growth hormone deficiency
• Recombinant DNA
• Subcutaneous injection

See Also

• Somatropin
• Pegvisomant
• Endocrinology

External Links

-